Hisashi Hosaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hisashi Hosaka has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Akihito Tsuji
Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kita, Japan
18 shared publications - Hideaki Suna
Ono Pharmaceutical Co., Ltd., Osaka, Osaka, Japan
18 shared publications - Hiroki Hara
Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan
18 shared publications - Hiroki Izumi
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
18 shared publications - Hiroshi Tanaka
Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan
18 shared publications - Katsunori Shinozaki
Division of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan
18 shared publications
Latest Publications
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Post-progression anti-cancer therapy of the nivolumab monotherapy
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Post-progression anti-cancer therapy of the nivolumab monotherapy
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Representativeness of study participants
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Representativeness of study participants
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
The antibodies list used for TIL analysis
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
The antibodies list used for TIL analysis
- Open Access
- 14 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Post-progression anti-cancer therapy of the nivolumab monotherapy
- 14 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Post-progression anti-cancer therapy of the nivolumab monotherapy
- Open Access
- 14 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Representativeness of study participants
- 14 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Representativeness of study participants
- Open Access
- 14 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
The antibodies list used for TIL analysis
- 14 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
The antibodies list used for TIL analysis
- Open Access
- 13 October 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Evaluation of PD-1+ Treg cells and PD-1+CD8+ T cells. A and B, The scatter plots that show PD-1 positivity (%) in CD8+ T cells and Treg cells in patients with (A) NSCLC and (B) gastric cancer (GC). Straight line indicates PD-1 positivity (%) in CD8+ T cells/PD-1 positivity (%) in Treg cells of ≥1.
- 13 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Evaluation of PD-1+ Treg cells and PD-1+CD8+ T cells. A and B, The scatter plots that show PD-1 positivity (%) in CD8+ T cells and Treg cells in patients with (A) NSCLC and (B) gastric cancer (GC). Straight line indicates PD-1 positivity (%) in CD8+ T cells/PD-1 positivity (%) in Treg cells of ≥1.
- Open Access
- 13 October 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Figure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
- 13 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Figure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
- Open Access
- 13 October 2025
- Published by American Association for Cancer Research (AACR)
Table 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Summary of conventional biomarkers (RES, ad hoc analysis).
- 13 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Summary of conventional biomarkers (RES, ad hoc analysis).
- Open Access
- 13 October 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Patient baseline characteristics (FAS).
- 13 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Patient baseline characteristics (FAS).